MyMD Pharmaceuticals Inc. (NASDAQ: MYMD) has experienced a rise in its stock price by 2.94 compared to its previous closing price of 0.68. However, the company has seen a fall of -10.26% in its stock price over the last five trading days. Business Wire reported 2023-08-02 that BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or the “Company”), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced statistically significant positive topline Phase 2 results for its next generation Oral TNF-α inhibitor MYMD-1 in Sarcopenia/Age-Related Frailty earlier this week. In conjunction with its release, the company also announced it will hold a confer.
Is It Worth Investing in MyMD Pharmaceuticals Inc. (NASDAQ: MYMD) Right Now?
, and the 36-month beta value for MYMD is at 2.24.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
The average price suggested by analysts for MYMD is $1536.00, The public float for MYMD is 37.72M, and currently, shorts hold a 7.83% of that float. The average trading volume for MYMD on September 15, 2023 was 730.08K shares.
MYMD’s Market Performance
MYMD stock saw a decrease of -10.26% in the past week, with a monthly decline of -45.10% and a quarterly a decrease of -54.84%. The volatility ratio for the week is 9.63%, and the volatility levels for the last 30 days are 9.30% for MyMD Pharmaceuticals Inc. (MYMD). The simple moving average for the past 20 days is -26.34% for MYMD’s stock, with a -56.06% simple moving average for the past 200 days.
MYMD Trading at -37.35% from the 50-Day Moving Average
After a stumble in the market that brought MYMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.03% of loss for the given period.
Volatility was left at 9.30%, however, over the last 30 days, the volatility rate increased by 9.63%, as shares sank -38.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.00% lower at present.
During the last 5 trading sessions, MYMD fell by -10.26%, which changed the moving average for the period of 200-days by -68.75% in comparison to the 20-day moving average, which settled at $0.9288. In addition, MyMD Pharmaceuticals Inc. saw -39.13% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MYMD starting from Rivard Paul, who purchase 150,000 shares at the price of $1.11 back on Aug 24. After this action, Rivard Paul now owns 400,000 shares of MyMD Pharmaceuticals Inc., valued at $166,500 using the latest closing price.
Rivard Paul, the Chief Legal Officer of MyMD Pharmaceuticals Inc., purchase 25,000 shares at $1.12 during a trade that took place back on Aug 17, which means that Rivard Paul is holding 250,000 shares at $28,080 based on the most recent closing price.
Stock Fundamentals for MYMD
Equity return is now at value -97.00, with -59.70 for asset returns.
Conclusion
In conclusion, MyMD Pharmaceuticals Inc. (MYMD) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
